Frank Gleeson is the founder of Satellos Bioscience. Latest round: Seed. Based in Canada.
Frank Gleeson is the Co-founder and CEO of Satellos Bioscience, a Canadian biotech company focused on developing a dystrophin-independent small molecule therapy for Duchenne muscular dystrophy (DMD). He announced the launch of Satellos in May after securing seed funding to advance drug discovery. The company is progressing from pre-clinical work towards its first human clinical trial.
Full founder directory · Investor directory · Company funding database · Fundraising library